Latest News and Press Releases

~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no...

~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~ ~ Additional regulatory update and guidance on the Biologics...

~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License...

IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of TD on quality of life regardless of a person’s underlying mental...

Dr Paulo Fontoura brings 20 years’ experience of working in the pharma industry, with the most recent 16 years focusing on translational medicine and clinical development approaches for one of the...

~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of disease progression in the...

~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington’s...

Newly established SAB of prominent geneticists, biologists and Huntington’s disease specialists’ marks pivotal step in accelerating progress of lead programme HRN001 Cambridge, UK, May 30, 2024:...

~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural...

New York, USA, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Huntington's Disease Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies to Watch Out - Prilenia, Neurocrine, Annexon,...